Albireo Pharma, Inc. (NASDAQ:ALBO) shares hit a new 52-week high during trading on Friday . The stock traded as high as $29.81 and last traded at $29.08, with a volume of 49300 shares. The stock had previously closed at $27.29.
Several research analysts have recently commented on the stock. ValuEngine lowered shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Wedbush restated an “outperform” rating and set a $58.00 price target on shares of Albireo Pharma in a research note on Monday, September 11th. Needham & Company LLC restated a “buy” rating on shares of Albireo Pharma in a research note on Thursday, October 26th. Roth Capital assumed coverage on shares of Albireo Pharma in a research note on Wednesday, November 15th. They set a “buy” rating and a $92.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of Albireo Pharma from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research note on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Albireo Pharma has a consensus rating of “Buy” and an average price target of $53.75.
In related news, major shareholder Plc Astrazeneca sold 500,000 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $21.40, for a total value of $10,700,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 22.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Albireo Pharma (ALBO) Reaches New 52-Week High at $29.81” was first posted by Equities Focus and is owned by of Equities Focus. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.equitiesfocus.com/2018/01/07/albireo-pharma-albo-reaches-new-52-week-high-at-29-81.html.
Albireo Pharma Company Profile
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.